Loading organizations...
§ Private Profile · San Francisco, CA, USA
AI-powered patient care management platform for chronic illness patients, improving medication adherence and disease management outcomes.
Catalia Health has raised $8.0M across 3 funding rounds.
Key people at Catalia Health.
Catalia Health has raised $8.0M in total across 3 funding rounds.
Based in San Francisco, California, Catalia Health develops an artificial intelligence-powered patient care management platform that utilizes interactive robotic interfaces to improve medication adherence for individuals with chronic illnesses. The company's core product, the Mabu robot, combines hardware, software, and psychological principles to engage patients daily across mobile, web, and physical interfaces, transmitting actionable health data back to healthcare providers. To scale its operations, the enterprise has raised approximately $10 million in total venture capital funding, which includes a $9 million seed round, and reached an early valuation of $4 million in 2016. Catalia Health has secured financial backing from prominent venture capital firms including Khosla Ventures, Ion Pacific, and Fusion Fund, while also partnering with organizations like Astellas Oncology to support cancer patients. The healthcare technology organization was founded in 2014 by Dr. Cory Kidd.
Catalia Health has raised $8.0M in total across 3 funding rounds.
Catalia Health's investors include Michael Joseph, Abstract Ventures, Amino Capital, Fusion Fund, LAUNCH, Long Journey Ventures, MBX Capital, Unruly Capital, Bill Smith, Erik Moore, Jaffray Woodriff, Sue Xu.
Catalia Health has raised $8.0M across 3 funding rounds. Most recently, it raised $4.0M Seed in November 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2017 | $4M Seed | Michael Joseph | Abstract Ventures, Amino Capital, Fusion Fund, LAUNCH, Long Journey Ventures, MBX Capital, Unruly Capital, Bill Smith, Erik Moore, Jaffray Woodriff, SUE XU, Tony Ling, Khosla Ventures, NewGen Ventures | Announced |
| Apr 1, 2017 | $3M Seed | Khosla Ventures | Abstract Ventures, Amino Capital, Fusion Fund, LAUNCH, Long Journey Ventures, MBX Capital, Surface Ventures, Unruly Capital, Bill Smith, Erik Moore, Jaffray Woodriff, Kenan Turnacioglu, SUE XU, DeNA, Flight Ventures, Innolinks Ventures, Lucky Capital, Macnica Ventures, Homan Yuen, Q Venture Partners Limited | Announced |
| Jun 1, 2015 | $1M Seed | Khosla Ventures | Abstract Ventures, Fusion Fund, Surface Ventures | Announced |
Key people at Catalia Health.
Catalia Health is a technology company that develops AI-powered patient engagement solutions, primarily through its flagship product, the Mabu robot and accompanying Care Insights Platform, to help patients manage chronic conditions like heart failure, rheumatoid arthritis, and kidney cancer.[1][2][3] It serves healthcare providers (e.g., Kaiser Permanente), pharmaceutical companies, and patients by delivering daily conversational coaching via robots, mobile apps, web interfaces, or text, focusing on medication adherence, symptom tracking, and personalized education while relaying anonymized data to care teams—replacing less engaging methods like phone calls.[1][2][3] The company has shown early traction through partnerships and patient retention, with users reluctant to return Mabu after trials, indicating strong growth potential in durable patient engagement.[1][2]
Catalia Health was founded in 2014 by Cory Kidd, who holds an SM '03 and PhD '08 from MIT in human-robot interaction from the MIT Media Lab.[1][3] Kidd's background in robotics and psychology drove the idea: recognizing the need to scale chronic disease management amid fragmented care, he created Mabu as an empathetic in-home companion to foster behavior change through natural conversations.[1][3][4] Early pivotal moments included a partnership with Kaiser Permanente around 2018 for heart failure patients, followed by expansions to rheumatoid arthritis and kidney cancer via pharma collaborations; patients' attachment to Mabu during studies validated the approach, with no out-of-pocket costs for users.[1][2]
Catalia Health stands out in healthcare tech through these key strengths:
Catalia Health rides the wave of AI in personalized chronic disease management, addressing fragmentation, medical errors (linked to ~10% of US deaths in 2016), and rising outpatient needs amid aging populations.[4] Timing aligns with advances in human-robot interaction and remote monitoring post-pandemic, amplified by pharma's demand for real-world evidence on specialty drugs.[1][2][3] Market forces like value-based care and readmission penalties favor scalable tools like Mabu, which augment—not replace—providers by enabling frequent, low-burden interactions.[3][4] It influences the ecosystem by pioneering consumer-facing AI that boosts adherence and data collection, paving the way for broader AI integration in home health without disrupting clinical workflows.[1][4]
Catalia Health is poised to expand its Mabu platform into more disease states and global markets, leveraging AI evolution for deeper personalization and predictive analytics amid booming digital therapeutics demand.[2][3][6] Trends like multimodal AI (voice, text, wearables) and regulatory tailwinds for patient engagement tech will accelerate growth, potentially through larger pharma partnerships or acquisitions by telehealth giants. Its influence may evolve from niche chronic care to ecosystem-wide data platforms, solidifying its role as a patient-centric innovator—echoing the early promise seen in patients who refused to part with their robotic coaches.[1]
